Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

29.53 +0.83 (+2.89%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roivant Sciences Ltd. - Common Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Why Is Roivant Sciences (ROIV) Stock Up Today? ↗
ROIV stock barely moved after the Roche deal, reflecting a down market and lack of movement on Roivant's other drug candidates. 
Via InvestorPlace
News headline image
Roche Spends $7.1 Billion On Roivant Drug, Following Merck, Sanofi Into The Raging Hot Immunology Space ↗
Roche is joining Merck and Sanofi in the TL1A drug space. These drugs could treat stomach diseases. 
Via Investor's Business Daily
News headline image
Roche Buys Pfizer & Roivant Sciences' Televant In ~$7.1B Deal ↗
Roche Holding AG (OTC: RHHBY) inked a deal to acquire  
Via Benzinga
News headline image
Why Troika Media Group Shares Are Trading Lower By Over 20%; Here Are 20 Stocks Moving Premarket ↗
Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 151.7% to $0.2190 in pre-market trading after the company reported a strategic collaboration with AstraZeneca and Everton in the Community to set... 
Via Benzinga
News headline image
What 8 Analyst Ratings Have To Say About Roivant Sciences ↗
 
Via Benzinga
News headline image
Analyst Expectations for Roivant Sciences's Future ↗
 
Via Benzinga
News headline image
What 9 Analyst Ratings Have To Say About Roivant Sciences ↗
 
Via Benzinga
News headline image
8 Analysts Have This to Say About Roivant Sciences ↗
 
Via Benzinga
News headline image
Textainer Group, Roivant Sciences And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗
U.S. stock futures traded lower this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
News headline image
Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant
From Roivant Sciences
Via GlobeNewswire
News headline image
Covant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer
From Covant Therapeutics
Via GlobeNewswire
News headline image
Teva Pharma Hooks Sanofi In $1.5 Billion Inflammation Deal. But Shares Tumble. ↗
The deal leans into the emerging TL1A drug class, potentially rivaling Roivant and Merck. 
Via Investor's Business Daily
News headline image
3 No-Brainer Growth Stocks to Buy in October ↗
These three top mid-cap stocks could be poised for a long-tailed growth spurt. 
Via The Motley Fool
News headline image
Why Immunovant Stock Is Bolting Higher Today ↗
The company may have best-in-class autoimmune disease therapy under its roof. 
Via The Motley Fool
News headline image
Johnson Controls International To Rally Over 27%? Here Are 10 Other Analyst Forecasts For Wednesday ↗
Keybanc cut the price target for Danaher Corporation (NYSE: DHR) from $325 to $300. Keybanc analyst Paul Knight maintained an Overweight rating. Danaher shares rose 0.6% to $248.75 in pre-market... 
Via Benzinga
News headline image
Roivant Stock Price Outlook: Strong Pipeline Is A Catalyst ↗
Roivant Sciences has 12 drugs in its pipeline. The company’s Immunovant subsidiary reported strong results for its drug. Roivant is in talks with Roche to sell its Chron’s disease for $7 billion. 
Via Talk Markets
News headline image
Why Shares of Immunovant Are Soaring on Tuesday ↗
Immunovant sees strong potential for an autoimmune disorder therapy. 
Via The Motley Fool
News headline image
Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares jumped 318.5% to $18.54 after the company released top-line results from randomized withdrawal period of study C602 of DCCR for Prader-Willi... 
Via Benzinga
News headline image
Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
News headline image
Why Is Autoimmune Disease-Focused Immunovant Stock Trading Higher Today? ↗
Immunovant Inc (NASDAQ: IMVT), a unit of Roivant Sciences Ltd (NASDAQ: ROIV), announced that subcutaneously administered doses of IMVT-1402 produced dose-dependent reductions in Immunoglobulin G (IgG)... 
Via Benzinga
News headline image
These 2 Biotech Stocks Are Bucking a Down Market Tuesday ↗
Stock index futures pointed to a lower open on Wall Street Tuesday morning. 
Via The Motley Fool
News headline image
Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant Announces Completion of Redemption of its Outstanding Warrants
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant Sciences: Is Vivek Ramaswamy’s Biotech Stock A Buy? ↗
Roivant Sciences stock price has entered a major bull run as investors remain optimistic about the company’s future. The shares surged to a high of $12.67 on Friday, reaching its highest level since... 
Via Talk Markets
News headline image
Vivek Ramaswamy's Parallels With Warren Buffett Run Deeper Than Wanting To Make Roivant The 'Berkshire Hathaway Of Drug Development' ↗
Presidential hopeful Vivek Ramaswamy and Warren Buffett may share different political ideologies but they have at least a couple of things in common. 
Via Benzinga
News headline image
2 Supercharged Growth Stocks Billionaires Can't Stop Buying ↗
A top hedge fund has been steadily buying these two growth stocks in 2023. 
Via The Motley Fool
News headline image
If You Invested $1000 In Vivek Ramaswamy-Founded Roivant When He Declared Presidential Bid, Here's How Much You'd Have Now ↗
Roivant stock has outperformed the broader market and the biotech sector this year, mirroring the rise in the fortunes of its founder Vivek Ramaswamy. 
Via Benzinga
News headline image
Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants
From Roivant Sciences
Via GlobeNewswire
News headline image
Top Biotech Roivant, Formed By Vivek Ramaswamy, Reports Steep Losses, Light Sales ↗
The company is working on a treatment for stomach diseases ulcerative colitis and Crohn's disease. 
Via Investor's Business Daily
News headline image
Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.